Stay updated on Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedSite banner updated to Revision: v3.4.2, and the prior government funding lapse notice has been removed.SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding notice banner was added, noting potential delays and that the NIH Clinical Center is open, and the site version updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThese updates are limited to UI/metadata changes (glossary display, capitalization tweaks, and a new version label). The core study content, eligibility criteria, endpoints, and results remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Location section has been updated with a large number of new sites across multiple regions and several sites removed, altering the map of where the study is conducted.SummaryDifference3%

- Check91 days agoChange DetectedPublication section wording updated to indicate publications are automatically filled from PubMed. Revision tag updated from v3.2.0 to v3.3.2.SummaryDifference0.6%

Stay in the know with updates to Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.